Core Viewpoint - The announcement from 加科思-B (01167) regarding the signing of a capital increase agreement and a share transfer agreement indicates a strategic move to enhance its stake in 加科瑞康, which focuses on cardiovascular drug development [1] Group 1: Financial Transactions - 加科思-B has entered into a capital increase agreement with 海松资本 and an industry partner, where 海松资本 will pay a total of RMB 2 billion, consisting of RMB 1.25 billion as an initial payment and RMB 750 million as a milestone payment for acquiring 80% of 加科瑞康 [1] - Following the completion of the transaction, 加科思-B will hold 10% of 加科瑞康, while 海松资本 will own 80%, and the industry partner will retain 10% [1] Group 2: Business Focus - 加科瑞康 specializes in the internal research and development of drugs for treating cardiovascular diseases and possesses intellectual property related to early-stage cardiovascular research and development projects [1]
港股异动 | 加科思-B(01167)高开近3% 附属北京加科思拟转让加科瑞康股权